1. ALLA AKTIER
  2. NYHETER
  3. SENZIME

Senzime

Nyheter Senzime Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Invitation to Senzime’s first quarter 2023 report presentation

Senzime invites investors, analysts, and media to a presentation of the interim report for the first quarter 2023 on April 28, 10:00 CEST. The report will be published at 8:30 CEST the same day.

During the presentation, Senzime’s CEO Pia Renaudin will present the report. A Q&A session will follow the presentation. The presentation will be held in English.

Date and time: Friday, April 28 10:00 CEST

The presentation can be followed live via webcast at: First Quarter Report Presentation

To participate via teleconference, please dial:

From Sweden: 010 884 80 16
From the UK: +44 808 189 0158
From the US: 1 855 9796 654
From all other locations +44 20 3936 2999

The access code 061633 should be used to access the conference. Make sure you are connected to the conference call by registering a few minutes before the conference begins.

Choices for participants who want to ask questions: Press *1 to ask a question, *2 to withdraw your question, or *0 for operator assistance.

After the presentation, a recording of the webcast will be available at senzime.com.

For further information, please contact:

Pia Renaudin, CEO of Senzime AB
Phone: +46 (0) 708 13 34 17, e-mail: pia.renaudin@senzime.com

Paula Treutiger, Head of Communication and IR
Phone: +46 (0) 733 66 65 99, e-mail: paula.treutiger@senzime.com

About Senzime

Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. Senzime’s employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications. The company markets an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.

Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world’s leading markets. The company’s shares are listed on Nasdaq Stockholm Main Market (SEZI). More information is available at senzime.com.

Attachments

Invitation to Senzime’s first quarter 2023 report presentation

Datum 2023-04-21, kl 10:00
Källa MFN
Bifogade filer
Invitation to Senzime’s first quarter 2023 report presentation